María Ochoa de Olza

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard A. Burris et al. · Clinical Cancer Research · 2019 · 286 citations · Full text

Medicine, Oncology, Pharmacology +17

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

Daniel P. Petrylak, Nicholas J. Vogelzang, Nikolay Budnik et al. · The Lancet Oncology · 2015 · 149 citations

Medicine, Oncology, Pharmacology +16

A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients

Margarita García, Rafael Moreno, Marta Gil-Martín et al. · Human Gene Therapy · 2018 · 111 citations · Full text

Life Sciences, Immunology, Oncology +17

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

Ignacio Matos, Juan Martín-Liberal, Alonso García-Ruiz et al. · Clinical Cancer Research · 2019 · 88 citations · Full text

Medicine, Immunology, Oncology +17

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Aung Naing, Justin F. Gainor, Hans Gelderblom et al. · Journal for ImmunoTherapy of Cancer · 2020 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17